- Home
- VRCA vs ANL Comparison
VRCA vs ANL Comparison
Compare VRCA & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VRCA | ANL |
|---|---|---|
| Founded | 2013 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.5M | 350.9M |
| IPO Year | 2018 | 2022 |
Fundamental Metrics
Financial Performance| Metric | VRCA | ANL |
|---|---|---|
| Price | $5.75 | $9.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $17.00 | $16.00 |
| AVG Volume (30 Days) | 116.1K | ★ 218.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $372.93 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.39 | $0.88 |
| 52 Week High | $9.82 | $12.09 |
Technical Indicators
Market Signals| Indicator | VRCA | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 44.49 | 55.38 |
| Support Level | $5.34 | $1.37 |
| Resistance Level | $6.44 | $10.15 |
| Average True Range (ATR) | 0.42 | 0.92 |
| MACD | 0.04 | -0.33 |
| Stochastic Oscillator | 49.10 | 53.74 |
Price Performance
Historical ComparisonAbout VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.